(97 days)
Ultrasound System TRINITY and its embedded 3D PROSTATE SUITE software are intended to be used by clinicians and their assistants. qualified to perform ultrasound diagnosis and ultrasound-guided procedures, in public or private hospitals. TRINITY is indicated to: · Generate ultrasound images for structural analysis and fluid flow analysis for o urology, o gynecology, o vascular. o abdominal, o small organs. o soft tissues and o musculoskeletal exams TRINITY is not indicated for ophthalmic and cranial ultrasonography. Medical Imaging Processing System 3D-PROSTATE SUITE, embedded on TRINITY or other KOELIS systems that do not integrate a 3D ultrasound module, is indicated to: · Process, visualize and record various 2D and 3D image modalities (such as Ultrasound images, MRI) · Fuse images of various modalities · Display organ and perform measurements · Display cartographies of prostate interventions (instrument positions) · Manage patient data · Import and export of data and images
TRINITY is an electro medical system considered as a system composed of: - A mobile workstation composed by a central unit with ultrasound beamformer, a tactile ● screen, a mouse, a touch pen and a footswitch, all assembled on a mobile cart. Options, as keyboard and trackball mouse, can be delivered. - 0 Ultrasonic probe: 2D/3D end-fire endocavity probe and/or 2D/3D side-fire endocavity probe. 2D probes can be optionally delivered. - 3D PROSTATE SUITE software composed of the base software and PROMAP –Ty that drives the 0 ultrasound module and performs additional measuring functions. The system generates ultrasound waves in the low megahertz range, typically from 1 Mhz to 20 Mhz. Two main ultrasound modes are provided by the system: B-mode imaging for structural analysis and Doppler imaging (including color flow sub-mode and power sub-mode) for body fluid flow analysis. - B-mode imaging measures the time and waveform differences between wave emission and o wave reception to reconstruct an image. - 0 Doppler imaging uses in addition the Doppler Effect to show flow direction and to inform about relative velocity (no measurement) (color flow sub-mode) or to show flow strength (power sub-mode). The system also provides 3D B-mode imaging for high quality ultrasound acquisition of anatomical volumes. The technology employed is volume-swept 3D ultrasound.
This document is a 510(k) Summary for the KOELIS TRINITY / 3D PROSTATE SUITE device. It establishes substantial equivalence to previously cleared devices rather than providing performance data against specific acceptance criteria for new features or AI-driven improvements. As such, it does not contain the detailed study information typically associated with proving a device meets acceptance criteria for novel algorithms, especially those involving AI.
Therefore, many of the requested fields cannot be directly populated from the provided text. The device is primarily an ultrasound system with associated software for processing and visualizing images, and the application focuses on expanding its indications for use and adding a new probe. The "Summary of Clinical Tests" explicitly states: "The subject of this premarket submission did not require clinical studies to support substantial equivalence."
Based on the provided text, here's an attempt to answer the questions:
1. A table of acceptance criteria and the reported device performance
The document does not provide a table of acceptance criteria with reported quantitative performance metrics for the TRINITY / 3D PROSTATE SUITE in the context of novel algorithmic performance or AI. The acceptance is based on demonstrating substantial equivalence to existing predicate devices for similar clinical applications and modalities, and compliance with various safety and performance standards.
The criteria for acceptance appear to be:
- Substantial Equivalence: Demonstrated through comparison of intended use, imaging capabilities, technological characteristics, scientific backgrounds, safety, and effectiveness to predicate devices (K160357 TRINITY and K160182 Logiq S7 expert).
- Safety Standards Compliance: Meeting voluntary standards for acoustic output, biocompatibility, cleaning/disinfection, thermal, electromagnetic, and mechanical safety (e.g., AAMI/ANSI ES60601-1, IEC60601-1-2, IEC60601-2-37, NEMA UD 3, ISO10993-1, NEMA UD 2, ISO14971, NEMA DICOM Set).
- Quality Assurance Measures: Application of risk analysis, requirements reviews, design reviews, varying levels of testing (unit, integration, final acceptance, performance, safety).
Since no new algorithmic performance (e.g., AI accuracy) is being claimed or evaluated, there are no reported quantitative performance metrics against these criteria beyond the statement that the device is "as safe, as effective, and performance is substantially equivalent to the predicate devices."
2. Sample size used for the test set and the data provenance
As stated, "The subject of this premarket submission did not require clinical studies to support substantial equivalence." Therefore, there is no clinical "test set" with patient data in the typical sense for evaluating a novel algorithm's performance. The "testing" referred to is against engineering and safety standards, not clinical performance on a dataset of images with ground truth.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable, as no clinical test set with ground truth established by experts for algorithmic performance evaluation was described as part of this submission.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
Not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No such study was conducted or reported in this 510(k) summary. The device's substantial equivalence is based on its core functionality as an ultrasound system and imaging processing system, not on AI assistance to human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This is not an AI-driven diagnostic algorithm. It's an imaging system and processing software. Therefore, the concept of "standalone performance" for an AI algorithm is not applicable here. The system's performance is intrinsically tied to its ability to generate, process, and display images for human interpretation and procedures.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
Not applicable, as no clinical performance study involving ground truth for an algorithm was conducted.
8. The sample size for the training set
Not applicable, as this is not an AI/ML submission describing a model trained on a dataset.
9. How the ground truth for the training set was established
Not applicable.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of three human profiles facing to the right, with a stylized design that resembles an eagle or bird in flight above them.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
KOELIS % Mrs. Laetitia Gervais Quality and Regulatory Affairs Manager 16. chemin du Vieux Chêne Meylan 38240 FRANCE
May 30, 2017
Re: K170521 Trade/Device Name: TRINITY/3D PROSTATE SUITE Regulation Number: 21 CFR 892.1550 Regulation Name: Ultrasonic pulsed doppler imaging system Regulatory Class: II Product Code: IYN, IYO, ITX, LLZ Dated: April 25, 2017 Received: April 27, 2017
Dear Mrs. Gervais:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael D'Hara
For
Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
510(k) Number (if known) K170521
Device Name TRINITY / 3D PROSTATE SUITE
Indications for Use (Describe) Ultrasound System TRINITY and its embedded 3D PROSTATE SUITE software are intended to be used by clinicians and their assistants. qualified to perform ultrasound diagnosis and ultrasound-guided procedures, in public or private hospitals. TRINITY is indicated to: · Generate ultrasound images for structural analysis and fluid flow analysis for o urology, o gynecology, o vascular. o abdominal, o small organs. o soft tissues and o musculoskeletal exams TRINITY is not indicated for ophthalmic and cranial ultrasonography. Medical Imaging Processing System 3D-PROSTATE SUITE, embedded on TRINITY or other KOELIS systems that do not integrate a 3D ultrasound module, is indicated to: · Process, visualize and record various 2D and 3D image modalities (such as Ultrasound images, MRI) · Fuse images of various modalities · Display organ and perform measurements · Display cartographies of prostate interventions (instrument positions) · Manage patient data · Import and export of data and images Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) CONTINUE ON A SEPARATE PAGE IF NEEDED.
{3}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
ANNEX: INDICATIONS FOR USE TABLES (FOUND IN SECTION 14)
The indications with clinical applications and exam types along with the modes of operation for TRINITY are recorded in the following tables.
Combinations identified "P" for the probes represents those previously cleared with this or another KOELIS Ultrasound system and those identified and "N" are new.
TRINITY
System: TRINITY
| Clinical Application | Mode of Operation | ||
|---|---|---|---|
| B [4] | B+Color Doppler [6] | Other (Notes) | |
| Ophtalmic | |||
| Fetal | |||
| Abdominal [1] | P | P | |
| Intra-operative (Specify) | |||
| Intra-operative (Neuro) | |||
| Laparoscopic | |||
| Pediatric | |||
| Small Organ [2] | P | P | |
| Neonatal Cephalic | |||
| Adult Cephalic | |||
| Transrectal | P | P | [5] |
| Trans-vaginal | P | P | |
| Trans-urethral | |||
| Trans-esoph. (non-Card.) | |||
| Musculo-skeletal(Conventional) | P | P | |
| Musculo-skeletal(Superficial) | P | P | |
| Intravascular | |||
| Other [3] | P | P | [5] |
| Cardiac Adult | |||
| Cardiac Pediatric | |||
| Intravascular (Cardiac) | |||
| Trans-esoph. (Cardiac) | |||
| Intra-cardiac | |||
| Other | |||
| Peripheral vessel | N | N | |
| Other |
{5}------------------------------------------------
NOTE
N = New indication; P =previously cleared by the FDA
- [1] Abdominal includes for instance in urology kidneys and bladder
- [2] Small organ includes for instance in urology scrotum and testicles
- [3] Other use includes Urology / Prostate
- [4] Includes volume-swept 3D B-Mode imaging
- [5] Needle guidance imaging
- [6] Combined modes are B+Color Doppler
2D Linear probe (K2DLN00)
System: TRINITY
Probe: 2D Linear probe (K2DLN00)
| Clinical Application | Mode of Operation | ||
|---|---|---|---|
| B | B+Color Doppler | Other (Notes) | |
| Ophtalmic | |||
| Fetal | |||
| Abdominal [1] | |||
| Intra-operative (Specify) | |||
| Intra-operative (Neuro) | |||
| Laparoscopic | |||
| Pediatric | |||
| Small Organ [2] | P | P | |
| Neonatal Cephalic | |||
| Adult Cephalic | |||
| Transrectal | |||
| Trans-vaginal | |||
| Trans-urethral | |||
| Trans-esoph. (non-Card.) | |||
| Musculo-skeletal(Conventional) | P | P | |
| Musculo-skeletal(Superficial) | P | P | |
| Intravascular | |||
| Other [3] | |||
| Cardiac Adult | |||
| Cardiac Pediatric | |||
| Intravascular (Cardiac) | |||
| Trans-esoph. (Cardiac) | |||
| Intra-cardiac |
{6}------------------------------------------------
| Clinical Application | Mode of Operation | ||
|---|---|---|---|
| B | B+Color Doppler | Other (Notes) | |
| Other | |||
| Peripheral vessel | N | N | |
| Other |
NOTE
N = New indication; P =previously cleared by FDA
[1] Abdominal includes for instance in urology kidneys and bladder
- [2] Small organ includes for instance in urology scrotum and testicles
- [3] Other use includes Urology / Prostate
2D abdominal probe (K2DAB00)
System: TRINITY
Probe: 2D abdominal probe (K2DAB00)
| Clinical Application | Mode of Operation | Other (Notes) | |
|---|---|---|---|
| B | B+Color Doppler | ||
| Ophtalmic | |||
| Fetal | |||
| Abdominal [1] | P | P | |
| Intra-operative (Specify) | |||
| Intra-operative (Neuro) | |||
| Laparoscopic | |||
| Pediatric | |||
| Small Organ [2] | |||
| Neonatal Cephalic | |||
| Adult Cephalic | |||
| Transrectal | |||
| Trans-vaginal | |||
| Trans-urethral | |||
| Trans-esoph. (non-Card.) | |||
| Musculo-skeletal(Conventional) | N | N | |
| Musculo-skeletal(Superficial) | N | N | |
| Intravascular | |||
| Other [3] | |||
| Cardiac Adult |
{7}------------------------------------------------
| Clinical Application | Mode of Operation | ||
|---|---|---|---|
| B | B+Color Doppler | Other (Notes) | |
| Cardiac Pediatric | |||
| Intravascular (Cardiac) | |||
| Trans-esoph. (Cardiac) | |||
| Intra-cardiac | |||
| Other | |||
| Peripheral vessel | |||
| Other |
NOTE
N = New indication; P =previoustly cleared by FDA
[1] Abdominal includes for instance in urology kidneys and bladder
[2] Small organ includes for instance in urology scrotum and testicles
[3] Other use includes Urology / Prostate
3D END-FIRE ENDOCAVITY PROBE (K3DEC00 / K3DEC00-2)
System: TRINITY
Probe: 3D end-fire endocavity probe (K3DEC00 / K3DEC00-2)
| Clinical Application | Mode of Operation | ||
|---|---|---|---|
| B [4] | B+Color Doppler | Other (Notes) | |
| Ophtalmic | |||
| Fetal | |||
| Abdominal [1] | |||
| Intra-operative (Specify) | |||
| Intra-operative (Neuro) | |||
| Laparoscopic | |||
| Pediatric | |||
| Small Organ [2] | |||
| Neonatal Cephalic | |||
| Adult Cephalic | |||
| Transrectal | P | P | [5] |
| Trans-vaginal | P | P | |
| Trans-urethral | |||
| Trans-esoph. (non-Card.) | |||
| Musculo-skeletal(Conventional) | |||
| Musculo-skeletal(Superficial) | |||
| Intravascular |
{8}------------------------------------------------
| Clinical Application | Mode of Operation | ||
|---|---|---|---|
| B [4] | B+Color Doppler | Other (Notes) [5] | |
| Other [3] | P | P | |
| Cardiac Adult | |||
| Cardiac Pediatric | |||
| Intravascular (Cardiac) | |||
| Trans-esoph. (Cardiac) | |||
| Intra-cardiac | |||
| Other | |||
| Peripheral vessel | |||
| Other |
NOTE
N = New indication; P =previoustly cleared by FDA
[1] Abdominal includes for instance in urology kidneys and bladder
[2] Small organ includes for instance in urology scrotum and testicles
[3] Other use includes Urology / Prostate
[4] Includes volume-swept 3D B-Mode imaging
[5] Needle guidance imaging
{9}------------------------------------------------
3D side-fire endocavity probe (K3DEL00)
System: TRINITY
Probe: 3D side-fire endocavity probe (K3DEL00)
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
| Mode of Operation | |||
|---|---|---|---|
| Clinical Application | B [4] | B+Color Doppler | Other (Notes) |
| Ophthalmic | |||
| Fetal | |||
| Abdominal [1] | |||
| Intra-operative (Specify) | |||
| Intra-operative (Neuro) | |||
| Laparoscopic | |||
| Pediatric | |||
| Small Organ [2] | |||
| Neonatal Cephalic | |||
| Adult Cephalic | |||
| Transrectal | N | N | [5] |
| Trans-vaginal | |||
| Trans-urethral | |||
| Trans-esoph. (non-Card.) | |||
| Musculo-skeletal(Conventional) | |||
| Musculo-skeletal(Superficial) | |||
| Intravascular | |||
| Other [3] | N | N | [5] |
| Cardiac Adult | |||
| Cardiac Pediatric | |||
| Intravascular (Cardiac) | |||
| Trans-esoph. (Cardiac) | |||
| Intra-cardiac | |||
| Other | |||
| Peripheral vessel | |||
| Other |
NOTE
N = New indication; P =previously cleared by FDA
[1] Abdominal includes for instance in urology kidneys and bladder
[2] Small organ includes for instance in urology scrotum and testicles
[3] Other use includes Urology / Prostate
[4] Includes volume-swept 3D B-Mode imaging
[5] Needle guidance imaging
{10}------------------------------------------------
| Image: KOELIS logo | 510 (K) SUMMARY | |||
|---|---|---|---|---|
| 510(k) Number: | K170521 | Version: | 2.0 | |
| Pr-Name: | TRINITY / 3D PROSTATESUITE | Date: | 2017.05.19 |
510(K) SUMMARY OR 510(K) STATEMENT
510(k) Summary for
The 510(k) summary is submitted in accordance with the requirements of.
| 510(k) Owner | KOELIS16, chemin du vieux chêne38240 MeylanFRANCEPhone: +33(0)4 58 17 68 10Fax: +33(0)4 58 17 68 24 |
|---|---|
| Contact Name: | Ms Laetitia GERVAISQuality and Regulatory Affairs ManagerMail: gervais@koelis.comPhone: +33(0)4 58 17 68 10Fax: +33(0)4 58 17 68 24 |
| Date Prepared | February 16, 2017 |
Proposed Device:
| Trade Name | TRINITY / 3D PROSTATE SUITE |
|---|---|
| Common Name | Ultrasound and Medical Imaging Processing System |
| Classification Name | Picture Archiving And Communications SystemUltrasonic Pulsed Doppler Imaging SystemUltrasonic Pulsed Echo Imaging SystemDiagnostic ultrasonic transducer |
| Device Class | Class II |
| Product Code | LLZ (21CFR 892.2050)IYN (21CFR 892.1550)IYO (21CFR 892.1560)ITX (21CFR 892.1570) |
Cleared Device:
The TRINITY is substantially equivalent to:
| 510(k) Number | Device Name |
|---|---|
| K160357 | TRINITY |
| K160182 | Logiq S7 expert |
| TITLE | 510 (K) SUMMARY | ID | K170521 | Page 1 of 5 |
|---|---|---|---|---|
| ------- | ----------------- | ---- | --------- | ------------- |
{11}------------------------------------------------
| 510 (K) SUMMARY | ||||
|---|---|---|---|---|
| Image: KOELIS logo | 510(k) Number: | K170521 | Version: | 2.0 |
| Pr-Name: | TRINITY / 3D PROSTATESUITE | Date: | 2017.05.19 |
Intended Use:
The Ultrasound System and Medical Imaging Processing System embedding 3D PROSTATE SUITE software and associated probes are intended for ultrasound diagnosis, ultrasound guided procedures and to process, visualize and record various image modalities.
Indications for Use:
Ultrasound System
TRINITY and its embedded 3D PROSTATE SUITE software are intended to be used by clinicians and their assistants, qualified to perform ultrasound diagnosis and ultrasound-guided procedures, in public or private hospitals.
TRINITY is indicated to:
- . Generate ultrasound images for structural analysis and fluid flow analysis for
- o urology,
- o gynecology,
- o vascular,
- o abdominal,
- small organs, o
- o soft tissues and
- o musculoskeletal
exams
TRINITY is not indicated for ophthalmic and cranial ultrasonography.
Medical Imaging Processing System
3D-PROSTATE SUITE, embedded on TRINITY or other KOELIS systems that do not integrate a 3D ultrasound module, is indicated to:
O Process, visualize and record various 2D and 3D image modalities (such as Ultrasound images, MRI)
- . Fuse images of various modalities
- . Display organs and perform measurements
- 0 Display cartographies of prostate interventions (instrument positions)
- Manage patient data
- 0 Import and export of data and images
| TITLE | 510 (K) SUMMARY | ID | K170521 | Page 2 of 5 |
|---|---|---|---|---|
| ------- | ----------------- | ---- | --------- | ------------- |
{12}------------------------------------------------
| 510 (K) SUMMARY | |||
|---|---|---|---|
| Image: KOELIS logo | 510(k) Number: | K170521 | Version: 2.0 |
| Pr-Name: | TRINITY / 3D PROSTATESUITE | Date: 2017.05.19 |
Patient population
All patients requiring an imaging exam (such as ultrasound scan exam) or an ultrasound-based intervention.
Contraindications
The ultrasound process system is not intended for the followings:
- Ophtalmic use or any use that would cause the acoustic beam to pass through the eye. 9
- Use in combination with high frequencies surgical devices 0
- 0 Use with a defibrillator while parts of the products are still in contact with the patient
- 0 Use when the atmosphere is oxygen enriched (>25%)
- Use when there is a risk of presence of flammable gas as anesthetic mix, oxygen or nitrous 0 oxide, close to the machine, to its screen or to its central unit
Device Description:
TRINITY is an electro medical system considered as a system composed of:
- A mobile workstation composed by a central unit with ultrasound beamformer, a tactile ● screen, a mouse, a touch pen and a footswitch, all assembled on a mobile cart. Options, as keyboard and trackball mouse, can be delivered.
- 0 Ultrasonic probe: 2D/3D end-fire endocavity probe and/or 2D/3D side-fire endocavity probe. 2D probes can be optionally delivered.
- 3D PROSTATE SUITE software composed of the base software and PROMAP –Ty that drives the 0 ultrasound module and performs additional measuring functions.
The system generates ultrasound waves in the low megahertz range, typically from 1 Mhz to 20 Mhz.
Two main ultrasound modes are provided by the system: B-mode imaging for structural analysis and Doppler imaging (including color flow sub-mode and power sub-mode) for body fluid flow analysis.
- B-mode imaging measures the time and waveform differences between wave emission and o wave reception to reconstruct an image.
- 0 Doppler imaging uses in addition the Doppler Effect to show flow direction and to inform about relative velocity (no measurement) (color flow sub-mode) or to show flow strength (power sub-mode).
The system also provides 3D B-mode imaging for high quality ultrasound acquisition of anatomical volumes. The technology employed is volume-swept 3D ultrasound.
| TITLE | 510 (K) SUMMARY | ID | K170521 | Page 3 of 5 |
|---|---|---|---|---|
| ------- | ----------------- | ---- | --------- | ------------- |
{13}------------------------------------------------
| 510 (K) SUMMARY | ||
|---|---|---|
| Image: KOELIS logo | 510(k) Number: K170521 | Version: 2.0 |
| Pr-Name: TRINITY / 3D PROSTATESUITE | Date: 2017.05.19 |
The clinician can control acoustic output intensity with the 71 and MI indices provided by the system. They indicate the level of thermal and mechanical stress that the system causes to the tissues, allowing the clinician to apply an ALARA-principle based exposure reduction strategy.
Technological Characteristics compared with the cleared devices:
TRINITY is substantially equivalent to the predicate devices with regard to intended use, imaging capabilities, technological characteristics, scientific backgrounds, safety and effectiveness. TRINITY and the predicate devices are intended for diagnostic and interventional ultrasound imaging.
TRINITY provides the same grayscale (B-Mode) and Color Doppler ultrasound imaging modes than its previous clearance K160357. The abdominal, linear and end-fire endocavity ultrasound probes of TRINITY are unchanged from its previous clearance K160357, the only difference consisting in a minor modification of one material of the enclosure of the end-fire endocavity probe. TRINITY generates, like its predicate devices, acoustic power levels that are below the applicable FDA limits. TRINITY has the same measurement, digital image capturing and reporting capabilities than the previous clearance K160357.
The differences with respect to the previous clearance K160357 of the TRINITY system are the addition of a side-fire endocavity ultrasound probe. The embedded 3D PROSTATE SUITE software was updated to support this probe. The range of indications of use of TRINITY was extended to include gynecology, vascular, soft tissues and musculoskeletal, which are also indications of use of predicate K160182.
Summary of Non-Clinical Tests
The device has been evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electromagnetic, and mechanical safety, and has been found to compliant with applicable medical device safety standards. TRINITY and its applications comply with voluntary standards:
-
AAMI/ANSI ES60601-1, Medical Electrical Equipment - Part 1: General Requirements for Safety
-
IEC60601-1-2, Medical Electrical Equipment - Part I - 2: General Requirements for Safety -Collateral Standard: Electromagnetic Compatibility Requirements and Tests
-
IEC60601-2-37, Medical Electrical Equipment – Part 2-37: Particular Requirements for the Safety of Ultrasonic Medical Diagnostic and Monitoring Equipment
-
NEMA UD 3, Standard for Real Time Display of Thermal and Mechanical Acoustic Output Indices on Diagnostic Ultrasound Equipment
| TITLE | 510 (K) SUMMARY | ID | K170521 | Page 4 of 5 |
|---|---|---|---|---|
| ------- | ----------------- | ---- | --------- | ------------- |
{14}------------------------------------------------
| Image: KOELIS logo | 510 (K) SUMMARY | |
|---|---|---|
| 510(k) Number: K170521 | Version: 2.0 | |
| Pr-Name: TRINITY / 3D PROSTATE SUITE | Date: 2017.05.19 |
-
ISO10993-1, Biological Evaluation of Medical Devices- Part 1: Evaluation and Testing
-
NEMA UD 2, Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment
7. ISO14971, Application of risk management to medical devices: Second edition
- NEMA Digital Imaging and Communications in Medicine (DICOM) Set. (Radiology)
The following quality assurance measures are applied to the development of the system:
- O Risk Analysis
- 0 Requirements Reviews
- 0 Design Reviews
- O Testing on unit level (Module verification)
- o Integration testing (System verification)
- 0 Final Acceptance Testing (Validation)
- 0 Performance testing (Verification)
- 0 Safety testing (Verification)
Probe materials and other patient contact materials are biocompatible.
Summary of Clinical Tests:
The subject of this premarket submission did not require clinical studies to support substantial equivalence.
Conclusion:
KOELIS considers TRINITY to be as safe, as effective, and performance is substantially equivalent to the predicate devices.
| TITLE | 510 (K) SUMMARY | ID | K170521 | Page 5 of 5 |
|---|---|---|---|---|
| ------- | ----------------- | ---- | --------- | ------------- |
§ 892.1550 Ultrasonic pulsed doppler imaging system.
(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.